![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
WK Eng, L Faucette, RK Johnson and R Sternglanz
Department of Biochemistry, State University of New York, Stony Brook 11794.
The budding yeast Saccharomyces cerevisiae and the fission yeast Schizosaccharomyces pombe are both sensitive to camptothecin, an inhibitor of DNA topoisomerase I. An S. cerevisiae DNA repair mutant, rad52, is hypersensitive to the drug. In both species, topoisomerase I mutants totally lacking the enzyme are completely resistant to the drug. A strain with a mutation leading to a temperature-sensitive topoisomerase I exhibits temperature dependence in its in vivo response to camptothecin. A strain carrying a plasmid that overproduces topoisomerase I is hypersensitive to the drug. The rad52 mutant is killed by overproduction of the enzyme, even in the absence of the drug. The response of several of these strains to camptothecin analogs, to DNA topoisomerase II inhibitors, and to other drugs is reported. The cytotoxic effects of camptothecin are discussed in terms of the drug extending the lifetime of a topoisomerase I-DNA covalent intermediate, which is recognized as DNA damage by a DNA repair system.
This article has been cited by other articles:
|
|
 |
|
  L.-C. Ma, C.-C. Kuo, J.-F. Liu, L.-T. Chen, and J.-Y. Chang Transcriptional Repression of O6-Methylguanine DNA Methyltransferase Gene Rendering Cells Hypersensitive to N,N'-Bis(2-chloroethyl)-N-nitrosurea in Camptothecin-Resistant Cells Mol. Pharmacol., August 1, 2008; 74(2): 517 - 526. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Sirikantaramas, M. Yamazaki, and K. Saito From the Cover: Mutations in topoisomerase I as a self-resistance mechanism coevolved with the production of the anticancer alkaloid camptothecin in plants PNAS, May 6, 2008; 105(18): 6782 - 6786. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Takagi, T. S. Dexheimer, C. Redon, O. Sordet, K. Agama, G. Lavielle, A. Pierre, S. E. Bates, and Y. Pommier Novel E-ring camptothecin keto analogues (S38809 and S39625) are stable, potent, and selective topoisomerase I inhibitors without being substrates of drug efflux transporters Mol. Cancer Ther., December 1, 2007; 6(12): 3229 - 3238. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-C. Kuo, J.-F. Liu, and J.-Y. Chang DNA Repair Enzyme, O6-Methylguanine DNA Methyltransferase, Modulates Cytotoxicity of Camptothecin-Derived Topoisomerase I Inhibitors J. Pharmacol. Exp. Ther., February 1, 2006; 316(2): 946 - 954. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Marchand, S. Antony, K. W. Kohn, M. Cushman, A. Ioanoviciu, B. L. Staker, A. B. Burgin, L. Stewart, and Y. Pommier A novel norindenoisoquinoline structure reveals a common interfacial inhibitor paradigm for ternary trapping of the topoisomerase I-DNA covalent complex. Mol. Cancer Ther., February 1, 2006; 5(2): 287 - 295. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. R. Jacquiau, R. C. A. M. van Waardenburg, R. J. D. Reid, M. H. Woo, H. Guo, E. S. Johnson, and M.-A. Bjornsti Defects in SUMO (Small Ubiquitin-related Modifier) Conjugation and Deconjugation Alter Cell Sensitivity to DNA Topoisomerase I-induced DNA Damage J. Biol. Chem., June 24, 2005; 280(25): 23566 - 23575. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-F. Marquis, I. Hardy, and M. Olivier Topoisomerase I Amino Acid Substitutions, Gly185Arg and Asp325Glu, Confer Camptothecin Resistance in Leishmania donovani Antimicrob. Agents Chemother., April 1, 2005; 49(4): 1441 - 1446. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Chatterjee, R. Digumarti, K. Katneni, V. V. Upreti, R. N. V. S. Mamidi, R. Mullangi, A. Surath, M. L. Srinivas, S. Uppalapati, S. Jiwatani, et al. Safety, Tolerability, and Pharmacokinetics of a Capsule Formulation of DRF-1042, a Novel Camptothecin Analog, in Refractory Cancer Patients in a Bridging Phase I Study J. Clin. Pharmacol., April 1, 2005; 45(4): 453 - 460. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Yu, E. Khan, M. A. Khaleque, J. Lee, G. Laco, G. Kohlhagen, S. Kharbanda, Y.-C. Cheng, Y. Pommier, and A. Bharti Phosphorylation of DNA Topoisomerase I by the c-Abl Tyrosine Kinase Confers Camptothecin Sensitivity J. Biol. Chem., December 10, 2004; 279(50): 51851 - 51861. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Mross, H. Richly, N. Schleucher, S. Korfee, M. Tewes, M. E. Scheulen, S. Seeber, T. Beinert, M. Schweigert, U. Sauer, et al. A phase I clinical and pharmacokinetic study of the camptothecin glycoconjugate, BAY 38-3441, as a daily infusion in patients with advanced solid tumors Ann. Onc., August 1, 2004; 15(8): 1284 - 1294. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Chatterjee, R. Digumarti, R. N. V. S. Mamidi, K. Katneni, V. V. Upreti, A. Surath, M. L. Srinivas, S. Uppalapati, S. Jiwatani, S. Subramaniam, et al. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of an Orally Active Novel Camptothecin Analog, DRF-1042, in Refractory Cancer Patients in a Phase I Dose Escalation Study J. Clin. Pharmacol., July 1, 2004; 44(7): 723 - 736. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. C.A.M. van Waardenburg, L. A. de Jong, F. van Delft, M. A.J. van Eijndhoven, M. Bohlander, M.-A. Bjornsti, J. Brouwer, and J. H.M. Schellens Homologous recombination is a highly conserved determinant of the synergistic cytotoxicity between cisplatin and DNA topoisomerase I poisons Mol. Cancer Ther., April 1, 2004; 3(4): 393 - 402. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Malik and J. L. Nitiss DNA Repair Functions That Control Sensitivity to Topoisomerase-Targeting Drugs Eukaryot. Cell, February 1, 2004; 3(1): 82 - 90. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Interthal, P. M. Quigley, W. G. J. Hol, and J. J. Champoux The Role of Lysine 532 in the Catalytic Mechanism of Human Topoisomerase I J. Biol. Chem., January 23, 2004; 279(4): 2984 - 2992. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. Braybrooke, E. Boven, N. P. Bates, R. Ruijter, N. Dobbs, P. D. Cheverton, H. M. Pinedo, and D. C. Talbot Phase I and pharmacokinetic study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f ), using a weekly 30-minute intravenous infusion, in patients with advanced solid malignancies Ann. Onc., June 1, 2003; 14(6): 913 - 921. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Bastin-Shanower, W. M. Fricke, J. R. Mullen, and S. J. Brill The Mechanism of Mus81-Mms4 Cleavage Site Selection Distinguishes It from the Homologous Endonuclease Rad1-Rad10 Mol. Cell. Biol., May 15, 2003; 23(10): 3487 - 3496. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-Y. Chang, J.-F. Liu, S.-H. Juang, T.-W. Liu, and L.-T. Chen Novel Mutation of Topoisomerase I in Rendering Cells Resistant to Camptothecin Cancer Res., July 1, 2002; 62(13): 3716 - 3721. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. H. Woo, J. R. Vance, A. R. O. Marcos, C. Bailly, and M.-A. Bjornsti Active Site Mutations in DNA Topoisomerase I Distinguish the Cytotoxic Activities of Camptothecin and the Indolocarbazole, Rebeccamycin J. Biol. Chem., February 1, 2002; 277(6): 3813 - 3822. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. B. Longley, P. R. Ferguson, J. Boyer, T. Latif, M. Lynch, P. Maxwell, D. P. Harkin, and P. G. Johnston Characterization of a Thymidylate Synthase (TS)-inducible Cell Line: A Model System for Studying Sensitivity to TS- and non-TS-targeted Chemotherapies Clin. Cancer Res., November 1, 2001; 7(11): 3533 - 3539. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. A. Stohr and K. N. Kreuzer Repair of Topoisomerase-Mediated DNA Damage in Bacteriophage T4 Genetics, May 1, 2001; 158(1): 19 - 28. [Abstract] [Full Text]
|
|
|
|
|
|
A. K. Larsen, C. Gilbert, G. Chyzak, S. Y. Plisov, I. Naguibneva, O. Lavergne, L. Lesueur-Ginot, and D. C. H. Bigg Unusual Potency of BN 80915, a Novel Fluorinated E-ring Modified Camptothecin, toward Human Colon Carcinoma Cells Cancer Res., April 1, 2001; 61(7): 2961 - 2967. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. E. Royce, P. M. Hoff, P. Dumas, Y. Lassere, J. J. Lee, J. Coyle, M. P. Ducharme, R. De Jager, and R. Pazdur Phase I and Pharmacokinetic Study of Exatecan Mesylate (DX-8951f): A Novel Camptothecin Analog J. Clin. Oncol., March 1, 2001; 19(5): 1493 - 1500. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. SALEEM, T. K. EDWARDS, Z. RASHEED, and E. H. RUBIN Mechanisms of Resistance to Camptothecins Ann. N.Y. Acad. Sci., December 1, 2000; 922(1): 46 - 55. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. CHAMPOUX Structure-Based Analysis of the Effects of Camptothecin on the Activities of Human Topoisomerase I Ann. N.Y. Acad. Sci., December 1, 2000; 922(1): 56 - 64. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. FIORANI and M.-A. BJORNSTI Mechanisms of DNA Topoisomerase I-Induced Cell Killing in the Yeast: Saccharomyces cerevisiae Ann. N.Y. Acad. Sci., December 1, 2000; 922(1): 65 - 75. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Perego, G. S. Jimenez, L. Gatti, S. B. Howell, and F. Zunino Yeast Mutants As a Model System for Identification of Determinants of Chemosensitivity Pharmacol. Rev., December 1, 2000; 52(4): 477 - 492. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Strumberg, A. A. Pilon, M. Smith, R. Hickey, L. Malkas, and Y. Pommier Conversion of Topoisomerase I Cleavage Complexes on the Leading Strand of Ribosomal DNA into 5'-Phosphorylated DNA Double-Strand Breaks by Replication Runoff Mol. Cell. Biol., June 1, 2000; 20(11): 3977 - 3987. [Abstract] [Full Text]
|
|
|
|
|
|
J. Fertala, J. R. Vance, P. Pourquier, Y. Pommier, and M.-A. Bjornsti Substitutions of Asn-726 in the Active Site of Yeast DNA Topoisomerase I Define Novel Mechanisms of Stabilizing the Covalent Enzyme-DNA Intermediate J. Biol. Chem., May 12, 2000; 275(20): 15246 - 15253. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. A. de Jonge, W. J. Loos, H. Gelderblom, A. S. Th. Planting, M. E. L. van der Burg, A. Sparreboom, E. Brouwer, V. van Beurden, M. A. Mantel, E. Doyle, et al. Phase I Pharmacologic Study of Oral Topotecan and Intravenous Cisplatin: Sequence-Dependent Hematologic Side Effects J. Clin. Oncol., May 10, 2000; 18(10): 2104 - 2115. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. H. Jensen, K. C. Nitiss, A. Rose, J. Dong, J. Zhou, T. Hu, N. Osheroff, P. B. Jensen, M. Sehested, and J. L. Nitiss A Novel Mechanism of Cell Killing by Anti-topoisomerase II Bisdioxopiperazines J. Biol. Chem., January 21, 2000; 275(3): 2137 - 2146. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Hong and K. N. Kreuzer An Antitumor Drug-Induced Topoisomerase Cleavage Complex Blocks a Bacteriophage T4 Replication Fork In Vivo Mol. Cell. Biol., January 15, 2000; 20(2): 594 - 603. [Abstract] [Full Text]
|
|
|
|
|
|
M. J. A. de Jonge, A. Sparreboom, A. S. T. Planting, M. E. L. van der Burg, M. M. de Boer-Dennert, J. t. Steeg, C. Jacques, and J. Verweij Phase I Study of 3-Week Schedule of Irinotecan Combined With Cisplatin in Patients With Advanced Solid Tumors J. Clin. Oncol., January 5, 2000; 18(1): 187 - 187. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Del Poeta, S.-F. Chen, D. Von Hoff, C. C. Dykstra, M. C. Wani, G. Manikumar, J. Heitman, M. E. Wall, and J. R. Perfect Comparison of In Vitro Activities of Camptothecin and Nitidine Derivatives against Fungal and Cancer Cells Antimicrob. Agents Chemother., December 1, 1999; 43(12): 2862 - 2868. [Abstract] [Full Text]
|
|
|
|
|
|
L. Stewart, G. C. Ireton, and J. J. Champoux A Functional Linker in Human Topoisomerase I Is Required for Maximum Sensitivity to Camptothecin in a DNA Relaxation Assay J. Biol. Chem., November 12, 1999; 274(46): 32950 - 32960. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Ducreux, M. Ychou, J.-F. Seitz, M. Bonnay, A. Bexon, J.-P. Armand, M. Mahjoubi, D. Mery-Mignard, and P. Rougier Irinotecan Combined With Bolus Fluorouracil, Continuous Infusion Fluorouracil, and High-Dose Leucovorin Every Two Weeks (LV5FU2 Regimen): A Clinical Dose-Finding and Pharmacokinetic Study in Patients With Pretreated Metastatic Colorectal Cancer J. Clin. Oncol., September 1, 1999; 17(9): 2901 - 2901. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Walowsky, D. J. Fitzhugh, I. B. Castano, J. Y. Ju, N. A. Levin, and M. F. Christman The Topoisomerase-related Function Gene TRF4 Affects Cellular Sensitivity to the Antitumor Agent Camptothecin J. Biol. Chem., March 12, 1999; 274(11): 7302 - 7308. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. L. Drengler, J. G. Kuhn, L. J. Schaaf, G. I. Rodriguez, M. A. Villalona-Calero, L. A. Hammond, J. A. Stephenson Jr., S. Hodges, M. A. Kraynak, B. A. Staton, et al. Phase I and Pharmacokinetic Trial of Oral Irinotecan Administered Daily for 5 Days Every 3 Weeks in Patients With Solid Tumors J. Clin. Oncol., February 1, 1999; 17(2): 685 - 685. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Wildner, R. M. Blaese, and J. C. Morris Therapy of Colon Cancer with Oncolytic Adenovirus Is Enhanced by the Addition of Herpes Simplex Virus-thymidine kinase Cancer Res., January 1, 1999; 59(2): 410 - 413. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Hann, D. L. Evans, J. Fertala, P. Benedetti, M.-A. Bjornsti, and D. J. Hall Increased Camptothecin Toxicity Induced in Mammalian Cells Expressing Saccharomyces cerevisiae DNA Topoisomerase I J. Biol. Chem., April 3, 1998; 273(14): 8425 - 8433. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. B. Saltz Clinical Use of Irinotecan:Current Status and Future Considerations Oncologist, December 1, 1997; 2(6): 402 - 409. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. D. Megonigal, J. Fertala, and M.-A. Bjornsti Alterations in the Catalytic Activity of Yeast DNA Topoisomerase I Result in Cell Cycle Arrest and Cell Death J. Biol. Chem., May 9, 1997; 272(19): 12801 - 12808. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. D. Reid, E. A. Kauh, and M.-A. Bjornsti Camptothecin Sensitivity Is Mediated by the Pleiotropic Drug Resistance Network in Yeast J. Biol. Chem., May 2, 1997; 272(18): 12091 - 12099. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. S. Hemenway and J. Heitman Immunosuppressant Target Protein FKBP12 Is Required for P-Glycoprotein Function in Yeast J. Biol. Chem., August 2, 1996; 271(31): 18527 - 18534. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Knab, J. Fertala, and M.-A. Bjornsti A Camptothecin-resistant DNA Topoisomerase I Mutant Exhibits Altered Sensitivities to Other DNA Topoisomerase Poisons J. Biol. Chem., March 17, 1995; 270(11): 6141 - 6148. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. C. Ireton, L. Stewart, L. H. Parker, and J. J. Champoux Expression of Human Topoisomerase I with a Partial Deletion of the Linker Region Yields Monomeric and Dimeric Enzymes That Respond Differently to Camptothecin J. Biol. Chem., August 11, 2000; 275(33): 25820 - 25830. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. K. Edwards, A. Saleem, J. A. Shaman, T. Dennis, C. Gerigk, E. Oliveros, M. R. Gartenberg, and E. H. Rubin Role for Nucleolin/Nsr1 in the Cellular Localization of Topoisomerase I J. Biol. Chem., November 10, 2000; 275(46): 36181 - 36188. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Lisby, J. R. Olesen, C. Skouboe, B. O. Krogh, T. Straub, F. Boege, S. Velmurugan, P. M. Martensen, A. H. Andersen, M. Jayaram, et al. Residues within the N-terminal Domain of Human Topoisomerase I Play a Direct Role in Relaxation* J. Biol. Chem., June 1, 2001; 276(23): 20220 - 20227. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
